Relationship between insulin resistance and β-cell dysfunction in subphenotypes of prediabetes and type 2 diabetes

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 2, 2015, Pages 707-716

  Færch, Kristine ^a   Johansen, Nanna B ^a,b   Witte, Daniel R ^c   Lauritzen, Torsten ^d   Jørgensen, Marit E ^a   Vistisen, Dorte ^a  

^a STENO DIABETES CENTER   (Denmark)

^b The Danish Diabetes Academy   (Denmark)

^c LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^d AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; GLUCOSE BLOOD LEVEL;

ABDOMINAL OBESITY; AGED; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PATIENT IDENTIFICATION; PRIORITY JOURNAL; ANALYSIS; BLOOD; BODY MASS; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; MIDDLE AGED; PHYSIOLOGY;

AGED; BLOOD GLUCOSE; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED; PREDIABETIC STATE;

EID: 84922576078     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-2853     Document Type: Article

References (39)

1. Perreault L, Færch K. Approaching pre-diabetes. J Diabetes Complications. 2014; 28(2): 226-233.
2. Færch K, Johansen NB, Vistisen D, Jørgensen ME. Cardiovascular risk stratification and management in pre-diabetes. Curr Diab Rep. 2014; 14: 493.
3. Færch K, Witte DR, Tabak AG, et al. Trajectories of cardiometabolic risk factors before diagnosis of three subtypes of type 2 diabetes: a post-hoc analysis of the longitudinal Whitehall II cohort study. Lancet Diabetes Endocrinol. 2013; 1(1): 43-51.
4. Tabák AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimäki M, Witte DR. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet. 2009; 373(9682): 2215-2221.
5. Qian L, Xu L, Wang X, et al. Early insulin secretion failure leads to diabetes in Chinese subjects with impaired glucose regulation. Diabetes Metab Res Rev. 2009; 25(2): 144-149.
6. Preis SR, Massaro JM, Robins SJ, et al. Abdominal subcutaneous and visceral adipose tissue and insulin resistance in the Framingham heart study. Obesity. 2010; 18(11): 2191-2198.
7. Wander PL, Boyko EJ, Leonetti DL, McNeely MJ, Kahn SE, Fujimoto WY. Change in visceral adiposity independently predicts a greater risk of developing type 2 diabetes over 10 years in Japanese Americans. Diabetes Care. 2013; 36(2): 289-293.
8. American Diabetes Association. Standards of medical care in diabetes - 2013. Diabetes Care. 2014; 37(suppl. 1): S14-S80.
9. World Health Organization. Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus. Abreviated Report of a WHO Consultation. Geneva: WHO Press, editor; 2011: 1-25.
10. Selvin E, Steffes MW, Zhu H, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med. 2010; 362(9): 800-811.
11. Barr EL, Boyko EJ, Zimmet PZ, Wolfe R, Tonkin AM, Shaw JE. Continuous relationships between non-diabetic hyperglycaemia and both cardiovascular disease and all-cause mortality: the Australian Diabetes, Obesity, and Lifestyle (AusDiab) study. Diabetologia. 2009; 52(3): 415-424.
12. Khaw KT, Wareham N, Luben R, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of european prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ. 2001; 322(7277): 15-18.
13. Lauritzen T, Griffin S, Borch-Johnsen K, Wareham NJ, Wolffenbuttel BH, Rutten G. The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with type 2 diabetes detected by screening. Int J Obes Relat Metab Disord. 2000; 24(Suppl. 3): S6-S11.
14. Johansen NB, Hansen AL, Jensen TM, et al. Protocol for ADDITION-PRO: a longitudinal cohort study of the cardiovascular experience of individuals at high risk for diabetes recruited from Danish primary care. BMC Public Health. 2012; 12: 1078.
15. Stolk RP, Wink O, Zelissen PM, Meijer R, van Gils AP, Grobbee DE. Validity and reproducibility of ultrasonography for the measurement of intra-abdominal adipose tissue. Int J Obes. 2001; 25(9): 1346-1351.
16. World Health Organization and International Diabetes Federation. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycaemia: Report of a WHO/IDF Consultation. Geneva: World Health Organization; 2006.
17. Gutt M, Davis CL, Spitzer SB, et al. Validation of the insulin sensitivity index (ISI0,120): comparison with other measures. Diabetes Res Clin Pract. 2000; 47(3): 177-184.
18. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28(7): 412-419.
19. Hansen T, Drivsholm T, Urhammer SA, et al. The BIGTT test: a novel test for simultaneous measurement of pancreatic β-cell function, insulin sensitivity, and glucose tolerance. Diabetes Care. 2007; 30(2): 257-262.
20. Færch K, Pacini G, Nolan JJ, Hansen T, Tura A, Vistisen D. Impact of glucose tolerance status, sex, and body size on glucose absorption patterns during OGTTs. Diabetes Care. 2013; 36(11): 3691-3697.
21. Færch K, Brøns C, Alibegovic AC, Vaag A. The disposition index: adjustment for peripheral vs. hepatic insulin sensitivity? J Physiol. 2010; 588(5): 759-764.
22. Benjamini Y, Hochberg Y. Controlling the false discovery rate - a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol. 1995; 57(1): 289-300.
23. Abdul-Ghani MA, Jenkinson CP, Richardson DK, Tripathy D, DeFronzo RA. Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance - results from the Veterans Administration genetic epidemiology study. Diabetes. 2006; 55(5): 1430-1435.
24. Færch K, Vaag A, Holst J, Glümer C, Pedersen O, Borch-Johnsen K. Impaired fasting glycaemia vs impaired glucose tolerance: similar impairment of pancreatic α and β cell function but differential roles of incretin hormones and insulin action. Diabetologia. 2008; 51(5): 853-861.
25. Meyer C, Szoke E, Pimenta W, et al. Different mechanisms for impaired fasting glucose and impaired postprandial glucose tolerance in humans. Diabetes Care. 2006; 29(8): 1909-1914.
26. Tripathy D, Almgren P, Tuomi T, Groop L. Contribution of insulin-stimulated glucose uptake and basal hepatic insulin sensitivity to surrogate measures of insulin sensitivity. Diabetes Care. 2004; 27(9): 2204-2210.
27. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003; 52(1): 102-110.
28. Kolb H, Mandrup-Poulsen T. The global diabetes epidemic as a consequence of lifestyle-induced low-grade inflammation. Diabetologia. 2010; 53(1): 10-20.
29. Jurgens CA, Toukatly MN, Fligner CL, et al. β-Cell loss and β-cell apoptosis in human type 2 diabetes are related to islet amyloid deposition. Am J Pathol. 2011; 178(6): 2632-2640.
30. Halban PA, Polonsky KS, Bowden DW, et al. β-Cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment. J Clin Endocrinol Metab. 2014; 99(6): 1983-1992.
31. O'Rahilly S, Hattersley A, Vaag A, Gray H. Insulin resistance as the major cause of impaired glucose tolerance: a self-fulfilling prophesy? Lancet. 1994; 344(8922): 585-589.
32. DeFronzo RA Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009; 58(4): 773-795.
33. Perreault L, Bergman BC, Playdon MC, la-Man C, Cobelli C, Eckel RH. Impaired fasting glucose with or without impaired glucose tolerance: progressive or parallel states of prediabetes? Am J Physiol Endocrinol Metab. 2008; 295(2): E428-E435.
34. Bianchi C, Miccoli R, Bonadonna RC, et al. Pathogenetic mechanisms and cardiovascular risk: differences between HbA1c and oral glucose tolerance test for the diagnosis of glucose tolerance. Diabetes Care. 2012; 35(12): 2607-2612.
35. Calanna S, Scicali R, Di Pino A, et al. α- and β-Cell abnormalities in haemoglobin A1c-defined prediabetes and type 2 diabetes. Acta Diabetol. 2014; 51(4): 567-575.
36. Tonjes A, Fasshauer M, Kratzsch J, Stumvoll M, Bluher M. Adipokine pattern in subjects with impaired fasting glucose and impaired glucose tolerance in comparison to normal glucose tolerance and diabetes. PLoS One. 2010; 5(11): e13911.
37. Silbernagel G, Sourij H, Grammer TB, et al. Isolated post-challenge hyperglycaemia predicts increased cardiovascular mortality. Atherosclerosis. 2012; 225(1): 194-199.
38. Xu Y, Wang L, He J. Prevalence and control of diabetes in chinese adults. JAMA. 2013; 310(9): 948-959.
39. Mooy JM, Grootenhuis PA, de Vries H, et al. Intra-individual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: the Hoorn Study. Diabetologia. 1996; 39(3): 298-305.